Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
van de Haar J, Ma X, Ooft SN, van der Helm PW, Hoes LR, Mainardi S, Pinato DJ, Sun K, Salvatore L, Tortora G, Zurlo IV, Leo S, Giampieri R, Berardi R, Gelsomino F, Merz V, Mazzuca F, Antonuzzo L, Rosati G, Stavraka C, Ross P, Rodriquenz MG, Pavarana M, Messina C, Iveson T, Zoratto F, Thomas A, Fenocchio E, Ratti M, Depetris I, Cergnul M, Morelli C, Libertini M, Parisi A, De Tursi M, Zanaletti N, Garrone O, Graham J, Longarini R, Gobba SM, Petrillo A, Tamburini E, La Verde N, Petrelli F, Ricci V, Wessels LFA, Ghidini M, Cortellini A, Voest EE, Valeri N. van de Haar J, et al. Among authors: zanaletti n. Nat Med. 2023 Mar;29(3):605-614. doi: 10.1038/s41591-023-02240-8. Epub 2023 Mar 2. Nat Med. 2023. PMID: 36864254 Free PMC article. Clinical Trial.
Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report.
De Stefano A, Zanaletti N, Cassata A, Silvestro L, Nappi A, Casaretti R, Romano C, Foschini F, Cardone C, Borrelli M, Petrillo A, Budillon A, Delrio P, Avallone A. De Stefano A, et al. Among authors: zanaletti n. Front Oncol. 2023 Feb 6;13:1084681. doi: 10.3389/fonc.2023.1084681. eCollection 2023. Front Oncol. 2023. PMID: 36814823 Free PMC article.
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.
Cardone C, De Stefano A, Rosati G, Cassata A, Silvestro L, Borrelli M, Di Gennaro E, Romano C, Nappi A, Zanaletti N, Foschini F, Casaretti R, Tatangelo F, Lastoria S, Raddi M, Bilancia D, Granata V, Setola S, Petrillo A, Vitagliano C, Gargiulo P, Arenare L, Febbraro A, Martinelli E, Ciardiello F, Delrio P, Budillon A, Piccirillo MC, Avallone A. Cardone C, et al. Among authors: zanaletti n. ESMO Open. 2023 Feb;8(1):100748. doi: 10.1016/j.esmoop.2022.100748. Epub 2023 Jan 3. ESMO Open. 2023. PMID: 36603521 Free PMC article. Clinical Trial.
Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials.
Tamburini E, Tassinari D, Ramundo M, De Stefano A, Viola MG, Romano C, Elia MT, Zanaletti N, Rudnas B, Casadei-Gardini A, Delrio P, Toma I, Granata V, Petrucelli L, Avallone A. Tamburini E, et al. Among authors: zanaletti n. Crit Rev Oncol Hematol. 2022 Apr;172:103627. doi: 10.1016/j.critrevonc.2022.103627. Epub 2022 Feb 22. Crit Rev Oncol Hematol. 2022. PMID: 35202817 Review.
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Antonetti P, Fargnoli MC, Porzio G, Salvatore L, Filippi R, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Dell'Aquila E, Lombardi P, Keränen SR, Depetris I, Giampieri R, Morelli C, De Tursi M, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Cortellini A, Pensieri MV, Ficorella C, Ferri C, Parisi A. Antonetti P, et al. Among authors: zanaletti n. Support Care Cancer. 2022 Mar;30(3):2455-2465. doi: 10.1007/s00520-021-06652-5. Epub 2021 Nov 15. Support Care Cancer. 2022. PMID: 34779921
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study.
Parisi A, Cortellini A, Venditti O, Filippi R, Salvatore L, Tortora G, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Fulgenzi C, Lombardi P, Roselló Keränen S, Depetris I, Giampieri R, Morelli C, Di Marino P, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Patruno L, D'Orazio C, Ficorella C, Ferri C, Porzio G. Parisi A, et al. Among authors: zanaletti n. Front Oncol. 2021 Oct 27;11:712053. doi: 10.3389/fonc.2021.712053. eCollection 2021. Front Oncol. 2021. PMID: 34778029 Free PMC article.
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, Ciardiello D, Terminiello M, Borrelli C, Vitiello PP, De Braud F, Morano F, Avallone A, Normanno N, Nappi A, Maiello E, Latiano T, Falcone A, Cremolini C, Rossini D, Santabarbara G, Pinto C, Santini D, Cardone C, Zanaletti N, Di Liello A, Renato D, Esposito L, Marrone F, Ciardiello F. Martinelli E, et al. Among authors: zanaletti n. JAMA Oncol. 2021 Oct 1;7(10):1529-1535. doi: 10.1001/jamaoncol.2021.2915. JAMA Oncol. 2021. PMID: 34382998 Free PMC article. Clinical Trial.
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
Parisi A, Porzio G, Cannita K, Venditti O, Avallone A, Filippi R, Salvatore L, Tortora G, Ribelli M, Nigro O, Gelsomino F, Spallanzani A, Zurlo V, Leo S, Dell'Aquila E, Claudia F, Lombardi P, Keränen SR, Aimar G, Depetris I, Giampieri R, Morelli C, De Tursi M, Tinari N, Di Pietro FR, De Galitiis F, Zanaletti N, Troiani T, Vitale P, Garajova I, Ghidini M, Spinelli GP, Zoratto F, Roberto M, Ierino D, Petrillo A, D'Orazio C, Ficorella C, Cortellini A. Parisi A, et al. Among authors: zanaletti n. Clin Colorectal Cancer. 2021 Dec;20(4):318-325. doi: 10.1016/j.clcc.2021.07.003. Epub 2021 Jul 18. Clin Colorectal Cancer. 2021. PMID: 34380594
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data.
Vitale P, Zanaletti N, Famiglietti V, De Falco V, Cervantes A, Rosellò S, Fenocchio E, Milanesio M, Lombardi P, Ciardiello D, Martini G, Martinelli E, Ciardiello F, Troiani T, Napolitano S. Vitale P, et al. Among authors: zanaletti n. Clin Colorectal Cancer. 2021 Sep;20(3):227-235. doi: 10.1016/j.clcc.2021.06.002. Epub 2021 Jun 10. Clin Colorectal Cancer. 2021. PMID: 34226142 Free article.
Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol.
Ottaiano A, Scala S, Santorsola M, Trotta AM, D'Alterio C, Portella L, Clemente O, Nappi A, Zanaletti N, De Stefano A, Avallone A, Granata V, Notariello C, Luce A, Lombardi A, Picone C, Petrillo A, Perri F, Tatangelo F, Di Mauro A, Albino V, Izzo F, Rega D, Pace U, Di Marzo M, Chiodini P, De Feo G, Del Prete P, Botti G, Delrio P, Caraglia M, Nasti G. Ottaiano A, et al. Among authors: zanaletti n. Ther Adv Med Oncol. 2021 Mar 24;13:1758835921989223. doi: 10.1177/1758835921989223. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33854566 Free PMC article.
19 results